Gwen Melincoff
Directeur/Membre du Conseil chez GAIN THERAPEUTICS, INC.
Fortune : 2 M $ au 31/05/2024
Profil
Gwen A.
Melincoff is currently serving as an Independent Director at Collegium Pharmaceutical, Inc., Soleno Therapeutics, Inc., Protalix Biotherapeutics, Inc., and Gain Therapeutics, Inc. She is also the Managing Director at Vodia Capital LLC.
In her former roles, Dr. Melincoff served as a Director at Naurex, Inc. and ArmaGen, Inc. She was an Independent Director at Photocure ASA from 2017 to 2020 and at Kamada Ltd.
from 2017 to 2018.
She also held positions as a Director at DBV Technologies SA, AM-Pharma BV, Enterome SA, and PROMETHERA Biosciences SA. Additionally, she served as an Independent Director at Tobira Therapeutics, Inc. from 2014 to 2016.
Dr. Melincoff held the position of Vice President-Business Development at Adolor Corp.
from 1999 to 2004 and at BTG International, Inc. from 2014 to 2016.
She was also the Senior Vice President-Corporate Development at Shire Plc and Senior Vice President-Business Development at Shire Pharmaceuticals, Inc. from 2004 to 2013.
Dr. Melincoff completed her undergraduate studies at George Washington University and her graduate studies at The Pennsylvania State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/05/2024 | 52 468 ( 0,16% ) | 2 M $ | 31/05/2024 | |
SOLENO THERAPEUTICS INC
0,00% | 01/04/2024 | 666 ( 0,00% ) | 28 025 $ | 31/05/2024 |
| 29/09/2023 | 0 ( -.--% ) | - $ | 31/05/2024 | |
GAIN THERAPEUTICS, INC.
-.--% | 25/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Gwen Melincoff
| Sociétés | Poste | Début |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Directeur/Membre du Conseil | 09/08/2017 |
| PROTALIX BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2019 |
| GAIN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2021 |
Vodia Capital LLC
 Vodia Capital LLC Investment ManagersFinance Part of Robertson Stephens Wealth Management LLC, Vodia Capital LLC provides investment advisory services. The company is based in Concord, MA. The company was founded by David B. Matias. David B. Matias has been the CEO since incorporation. Vodia Capital was acquired by Robertson Stephens Wealth Management LLC on December 13, 2022. | Corporate Officer/Principal | - |
Anciens postes connus de Gwen Melincoff
| Sociétés | Poste | Fin |
|---|---|---|
| SOLENO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 06/06/2024 |
| PHOTOCURE ASA | Directeur/Membre du Conseil | 10/06/2020 |
| KAMADA LTD. | Directeur/Membre du Conseil | 20/12/2018 |
| TOBIRA THERAPEUTICS INC | Directeur/Membre du Conseil | 31/10/2016 |
BTG International, Inc.
 BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Corporate Officer/Principal | 01/09/2016 |
Formation de Gwen Melincoff
| George Washington University | Undergraduate Degree |
| The Pennsylvania State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| SOLENO THERAPEUTICS, INC. | Health Technology |
| PHOTOCURE ASA | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| KAMADA LTD. | Health Technology |
| PROTALIX BIOTHERAPEUTICS, INC. | Health Technology |
| GAIN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
BTG International, Inc.
BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Finance |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Vodia Capital LLC
Vodia Capital LLC Investment ManagersFinance Part of Robertson Stephens Wealth Management LLC, Vodia Capital LLC provides investment advisory services. The company is based in Concord, MA. The company was founded by David B. Matias. David B. Matias has been the CEO since incorporation. Vodia Capital was acquired by Robertson Stephens Wealth Management LLC on December 13, 2022. | Finance |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on September 11, 2006 and is headquartered in Madison, NJ. | Health Technology |
